Concepedia

Stephan Chalon

SC

Statistics

Publications

41

Citations

2K

H-Index

29

Active since

1993

Affiliations

Medicines for Malaria Venture(Current)

QIMR Berghofer Medical Research Institute

The University of Queensland

Pfizer (United States)

VA Palo Alto Health Care System

Stephan Chalon is an author at Medicines for Malaria Venture specializing in pharmacology, clinical pharmacology, and medicine.

ORCID

Publications per year

1993–2022

41

Publications

41

A controlled human malaria infection model enabling evaluation of transmission-blocking interventions

Katharine A. Collins, Claire Wang, Matthew Adams et al. · Journal of Clinical Investigation · 2018 · 151 citations · Full text

, , +17

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

James McCarthy, Julie Lotharius, Thomas Rückle et al. · The Lancet Infectious Diseases · 2017 · 127 citations · Full text

, , +13

Pharmacokinetics of intravenous and oral L‐arginine in normal volunteers

Oranee Tangphao, Stephan Chalon, Brian B. Hoffman et al. · British Journal of Clinical Pharmacology · 1999 · 114 citations · Full text

, , +13

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection

Mihály Sulyok, Thomas Rückle, Alexandra Roth et al. · The Lancet Infectious Diseases · 2017 · 104 citations · Full text

, , +17

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Stephan Chalon, Luc‐André Granier, François Vandenhende et al. · Neuropsychopharmacology · 2003 · 94 citations

, , +16

1–5 of 41